Applied DNA Sciences (APDN)
(Delayed Data from NSDQ)
$2.54 USD
+0.71 (38.80%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.48 -0.06 (-2.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APDN 2.54 +0.71(38.80%)
Will APDN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APDN
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
APDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Applied DNA Sciences (APDN) Tops Q3 Earnings Estimates
Axon Enterprise (AXON) Q2 Earnings and Revenues Top Estimates
Ball (BALL) Q2 Earnings Beat Estimates
Other News for APDN
Wall Street Breakfast: What Moved Markets
Applied DNA submits validation package to NYS Department of Health
Applied DNA Sciences rating updated to Under Review at H.C. Wainwright
Mpox stocks in focus as Thailand reports first case in Asia linked to new strain
Bavarian Nordic rebounds as new mpox vaccine order boosts outlook